ESTRO 2024 - Abstract Book

S3868

Physics - Image acquisition and processing

ESTRO 2024

We developed a novel method for identifying significant intensity changes in longitudinal MR images acquired routinely at an MR-Linac. Feasibility was tested in daily TrueFISP images of glioblastoma patients at an MR-Linac, which showed heterogeneous longitudinal intensity changes for different patients. The ability to detect these changes on a patient level may enable a more individualized selection of the target volume. Future work may focus on differentiating intensity changes due to deformation from those due to tissue changes.

Keywords: MR-Linac, Glioblastoma, Longitudinal Imaging

References:

[1] B. Avants, N. J. Tustison, and G. Song, “Advanced Normalization Tools: V1.0,” The Insight Journal. NumFOCUS - Insight Software Consortium (ITK), Jul. 29, 2009. doi: 10.54294/uvnhin.

[2] N. J. Tustison et al., “N4ITK: Improved N3 Bias Correction,” IEEE Transactions on Medical Imaging, vol. 29, no. 6. Institute of Electrical and Electronics Engineers (IEEE), pp. 1310–1320, Jun. 2010. doi: 10.1109/tmi.2010.2046908.

[3] P. Wallimann et al., “N-Peaks, a novel method of intensity normalization for magnetic resonance images,” presented at the 55th SSRMP Annual Meeting , Thun, Switzerland, p. 36, Oct. 27-28, 2022.

1799

Mini-Oral

AI-based synthetic stopping power maps for accurate MRI-only proton therapy in primary brain tumors

Emilie Alvarez Andres 1,2 , Daniel Zachow 1,2 , Nils Peters 1,3 , Felix Raschke 1,4 , Franciska Lebbink 1,2,5 , Christian Richter 1,2,4 , Rudi Apolle 5 , Esther G. C. Troost 1,2,4 1 OncoRay – National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden; Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany. 2 Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus of Technische Universität Dresden, Dresden, Germany. 3 Massachusetts General Hospital and Harvard Medical School, Department of Radiation Oncology, Boston, MA, USA. 4 Institute of Radiooncology – OncoRay, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany. 5 National Center for Tumor Diseases (NCT/UCC), Dresden, Germany: German Cancer Research Center (DKFZ), Heidelberg, Germany; Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany

Purpose/Objective:

Proton Therapy (PT) is a popular radiation modality in the treatment of primary brain tumour patients, since it is capable of sparing healthy tissues surrounding the Clinical Target Volume (CTV) defined by the primary tumor or its